biomarkers for glp-1 agonists RAs Reduce Inflammation and MACE Beyond Weight Loss | Farouc Jaffer posted on the topic GLP-1 Receptor Agonist Market Forecast

The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74

The GLP-1R stalk sequence 126- EESKRGERSS 137 is highly entropic, which may contribute to its disorder in current and previous GLP-1RGs structures

Funding Funding was provided by Novo Nordisk which manufactures semaglutide

Im like: Whats next

doi: 10.2337/diabetes.53.9.2492 [DOI] [PubMed] [Google Scholar] 93

The correct posture is enthusiasm about the science paired with sobriety about the still-open Phase 3 and safety questions